

# Andreas A Argyriou

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8201453/publications.pdf>

Version: 2024-02-01

99  
papers

3,298  
citations

186209

28  
h-index

161767

54  
g-index

99  
all docs

99  
docs citations

99  
times ranked

3702  
citing authors

#	ARTICLE	IF	CITATIONS
1	Isolated optic neuritis after pembrolizumab administration for non-small-cell lung carcinoma. <i>International Journal of Neuroscience</i> , 2022, 132, 643-648.	0.8	13
2	Serum neurofilament light chain levels as biomarker of paclitaxel-induced cognitive impairment in patients with breast cancer: a prospective study. <i>Supportive Care in Cancer</i> , 2022, 30, 1807-1814.	1.0	9
3	Optimal outcome measures for assessing exercise and rehabilitation approaches in chemotherapy-induced peripheral-neurotoxicity: Systematic review and consensus expert opinion. <i>Expert Review of Neurotherapeutics</i> , 2022, 22, 65-76.	1.4	11
4	Long-term adherence, safety, and efficacy of repeated onabotulinumtoxinA over five years in chronic migraine prophylaxis. <i>Acta Neurologica Scandinavica</i> , 2022, 145, 676-683.	1.0	12
5	Rehabilitation, exercise, and related non-pharmacological interventions for chemotherapy-induced peripheral neurotoxicity: Systematic review and evidence-based recommendations. <i>Critical Reviews in Oncology/Hematology</i> , 2022, 171, 103575.	2.0	18
6	Prospectively assessing serum neurofilament light chain levels as a biomarker of <scp>paclitaxel-induced</scp> peripheral neurotoxicity in breast cancer patients. <i>Journal of the Peripheral Nervous System</i> , 2022, 27, 166-174.	1.4	21
7	Assessing the Significance of the Circadian Time of Administration on the Effectiveness and Tolerability of OnabotulinumtoxinA for Chronic Migraine Prophylaxis. <i>Toxins</i> , 2022, 14, 296.	1.5	3
8	A systematic review with expert opinion on the role of gepants for the preventive and abortive treatment of migraine. <i>Expert Review of Neurotherapeutics</i> , 2022, 22, 469-488.	1.4	6
9	Prospective Comparison of Longer Needle Lengths to Assess the Risk of OnabotulinumtoxinA-Associated Neck Pain in Patients with Chronic Migraine. <i>Toxins</i> , 2022, 14, 434.	1.5	3
10	Recently available and emerging therapeutic strategies for the acute and prophylactic management of cluster headache: a systematic review and expert opinion. <i>Expert Review of Neurotherapeutics</i> , 2021, 21, 235-248.	1.4	7
11	Oxaliplatin rechallenge in metastatic colorectal cancer patients with clinically significant oxaliplatin-induced peripheral neurotoxicity. <i>Journal of the Peripheral Nervous System</i> , 2021, 26, 43-48.	1.4	5
12	NF- $\beta$ 2 and RELB offer prognostic information in colorectal cancer and NFKB2 rs7897947 represents a genetic risk factor for disease development. <i>Translational Oncology</i> , 2021, 14, 100912.	1.7	2
13	Duloxetine against symptomatic chemotherapy-induced peripheral neurotoxicity in cancer survivors: a real world, open-label experience. <i>Anti-Cancer Drugs</i> , 2021, 32, 88-94.	0.7	8
14	Bee sting-induced acute ischemic stroke: A new manifestation of kounis syndrome?. <i>Annals of Indian Academy of Neurology</i> , 2021, 24, 118-120.	0.2	0
15	An updated brief overview on post-traumatic headache and a systematic review of the non-pharmacological interventions for its management. <i>Expert Review of Neurotherapeutics</i> , 2021, 21, 475-490.	1.4	18
16	Perilesional edema in brain metastases as predictive factor of response to systemic therapy in non-small cell lung cancer patients: a preliminary study. <i>Annals of Translational Medicine</i> , 2021, 9, 648-648.	0.7	2
17	Neuromuscular complications of cancer therapy. <i>Current Opinion in Neurology</i> , 2021, 34, 658-668.	1.8	4
18	Prospective Evaluation of Health Care Provider and Patient Assessments in Chemotherapy-Induced Peripheral Neurotoxicity. <i>Neurology</i> , 2021, 97, e660-e672.	1.5	16

#	ARTICLE	IF	CITATIONS
19	Predictive Biomarkers of Oxaliplatin-Induced Peripheral Neurotoxicity. <i>Journal of Personalized Medicine</i> , 2021, 11, 669.	1.1	8
20	Beyond chronic migraine: a systematic review and expert opinion on the off-label use of botulinum neurotoxin type-A in other primary headache disorders. <i>Expert Review of Neurotherapeutics</i> , 2021, 21, 923-944.	1.4	12
21	Open Label Prospective Experience of Supplementation with a Fixed Combination of Magnesium, Vitamin B2, Feverfew, <i>Andrographis Paniculata</i> and Coenzyme Q10 for Episodic Migraine Prophylaxis. <i>Journal of Clinical Medicine</i> , 2021, 10, 67.	1.0	7
22	Natural Course of Neurotoxicity after Immune Checkpoint Inhibitor (ICI) Exposure. , 2021, , 253-260.		0
23	Natural History of Chemotherapy-Induced Peripheral Neuropathy. , 2021, , 1-18.		1
24	Assessing risk factors of falls in cancer patients with chemotherapy-induced peripheral neurotoxicity. <i>Supportive Care in Cancer</i> , 2020, 28, 1991-1995.	1.0	17
25	Irreversible diffuse hypoxic-ischemic encephalopathy, secondary to type I Kounis syndrome. <i>International Journal of Neuroscience</i> , 2020, 130, 746-748.	0.8	2
26	Emerging pharmacological strategies for the management of chemotherapy-induced peripheral neurotoxicity (CIPN), based on novel CIPN mechanisms. <i>Expert Review of Neurotherapeutics</i> , 2020, 20, 1005-1016.	1.4	16
27	A Radiomics Model for Predicting the Response to Bevacizumab in Brain Necrosis after Radiotherapy. <i>Clinical Cancer Research</i> , 2020, 26, 5438-5447.	3.2	32
28	Immune-Driven Pathogenesis of Neurotoxicity after Exposure of Cancer Patients to Immune Checkpoint Inhibitors. <i>International Journal of Molecular Sciences</i> , 2020, 21, 5774.	1.8	23
29	Incidence and characteristics of neurotoxicity in immune checkpoint inhibitors with focus on neuromuscular events: Experience beyond the clinical trials. <i>Journal of the Peripheral Nervous System</i> , 2020, 25, 171-177.	1.4	32
30	The Fire Within: NF- $\kappa$ B Involvement in Non-Small Cell Lung Cancer. <i>Cancer Research</i> , 2020, 80, 4025-4036.	0.4	34
31	A nomogram to predict symptomatic epilepsy in patients with radiation-induced brain necrosis. <i>Neurology</i> , 2020, 95, e1392-e1403.	1.5	13
32	Real world, open label experience with lacosamide against acute painful oxaliplatin-induced peripheral neurotoxicity. <i>Journal of the Peripheral Nervous System</i> , 2020, 25, 178-183.	1.4	8
33	Pneumococcal Otogenic Meningitis Complicated With Pneumocephalus and Coma State. <i>Cureus</i> , 2020, 12, e10917.	0.2	1
34	Immune checkpoint inhibitors-induced neuromuscular toxicity: From pathogenesis to treatment. <i>Journal of the Peripheral Nervous System</i> , 2019, 24, S74-S85.	1.4	42
35	Neurophysiological, nerve imaging and other techniques to assess chemotherapy-induced peripheral neurotoxicity in the clinical and research settings. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2019, 90, jnnp-2019-320969.	0.9	43
36	Voltage-gated sodium channel dysfunction and the search for other satellite channels in relation to acute oxaliplatin-induced peripheral neurotoxicity. <i>Journal of the Peripheral Nervous System</i> , 2019, 24, 360-361.	1.4	4

#	ARTICLE	IF	CITATIONS
37	Liability of the voltage-gated potassium channel KCNN3 repeat polymorphism to acute oxaliplatin-induced peripheral neurotoxicity. <i>Journal of the Peripheral Nervous System</i> , 2019, 24, 298-303.	1.4	11
38	Taxane and epothilone-induced peripheral neurotoxicity: From pathogenesis to treatment. <i>Journal of the Peripheral Nervous System</i> , 2019, 24, S40-S51.	1.4	33
39	Bortezomib and other proteasome inhibitors-induced peripheral neurotoxicity: From pathogenesis to treatment. <i>Journal of the Peripheral Nervous System</i> , 2019, 24, S52-S62.	1.4	30
40	The Toxic Neuropathy Consortium of the Peripheral Nerve Society. <i>Journal of the Peripheral Nervous System</i> , 2019, 24, S4-S5.	1.4	3
41	Overview and critical revision of clinical assessment tools in chemotherapy-induced peripheral neurotoxicity. <i>Journal of the Peripheral Nervous System</i> , 2019, 24, S13-S25.	1.4	34
42	Vinca alkaloids, thalidomide and eribulin-induced peripheral neurotoxicity: From pathogenesis to treatment. <i>Journal of the Peripheral Nervous System</i> , 2019, 24, S63-S73.	1.4	32
43	Chemotherapy-induced peripheral neurotoxicity: A multifaceted, still unsolved issue. <i>Journal of the Peripheral Nervous System</i> , 2019, 24, S6-S12.	1.4	37
44	Expression Of Intracellular Components of the NF- $\kappa$ B Alternative Pathway (NF- $\kappa$ B2, RelB, NIK and Bcl3) is Associated With Clinical Outcome of NSCLC Patients. <i>Scientific Reports</i> , 2019, 9, 14299.	1.6	14
45	Patients' and physicians' interpretation of chemotherapy-induced peripheral neurotoxicity. <i>Journal of the Peripheral Nervous System</i> , 2019, 24, 111-119.	1.4	20
46	Expression of Immune System-Related Membrane Receptors CD40, RANK, BAFFR and LT $\beta$ R is Associated with Clinical Outcome of Operated Non-Small-Cell Lung Cancer Patients. <i>Journal of Clinical Medicine</i> , 2019, 8, 741.	1.0	10
47	Effect of Pregabalin on Radiotherapy-Related Neuropathic Pain in Patients With Head and Neck Cancer: A Randomized Controlled Trial. <i>Journal of Clinical Oncology</i> , 2019, 37, 135-143.	0.8	36
48	Acute aseptic meningitis during isotretinoin treatment for nodular acne solely presenting with headache: case report and brief review of the literature. <i>International Journal of Neuroscience</i> , 2019, 129, 181-183.	0.8	3
49	Risk stratification of oxaliplatin induced peripheral neurotoxicity applying electrophysiological testing of dorsal sural nerve. <i>Supportive Care in Cancer</i> , 2018, 26, 3143-3151.	1.0	23
50	NF- $\kappa$ B2 Genetic Variations are Significantly Associated with Non-Small Cell Lung Cancer Risk and Overall Survival. <i>Scientific Reports</i> , 2018, 8, 5259.	1.6	8
51	Efficacy of a Novel Sigma-1 Receptor Antagonist for Oxaliplatin-Induced Neuropathy: A Randomized, Double-Blind, Placebo-Controlled Phase IIa Clinical Trial. <i>Neurotherapeutics</i> , 2018, 15, 178-189.	2.1	92
52	Neurobrucellosis presenting as clinically definite amyotrophic lateral sclerosis. <i>International Journal of Neuroscience</i> , 2018, 128, 686-688.	0.8	4
53	Sustained onabotulinumtoxinA therapeutic benefits in patients with chronic migraine over 3 years of treatment. <i>Journal of Headache and Pain</i> , 2018, 19, 87.	2.5	28
54	Inconclusive evidence to support the use of minimally-invasive radiofrequency denervation against chronic low back pain. <i>Annals of Translational Medicine</i> , 2018, 6, 127-127.	0.7	3

#	ARTICLE	IF	CITATIONS
55	Sphingolipid metabolism products: potential new players in the pathogenesis of bortezomib-induced neuropathic pain. <i>Annals of Translational Medicine</i> , 2018, 6, S78-S78.	0.7	1
56	Chemotherapy-induced peripheral neurotoxicity: management informed by pharmacogenetics. <i>Nature Reviews Neurology</i> , 2017, 13, 492-504.	4.9	68
57	Onabotulinumtoxin-A treatment in Greek patients with chronic migraine. <i>Journal of Headache and Pain</i> , 2016, 17, 84.	2.5	27
58	Genetic determinants of chronic oxaliplatin-induced peripheral neurotoxicity: a genome-wide study replication and meta-analysis. <i>Journal of the Peripheral Nervous System</i> , 2015, 20, 15-23.	1.4	34
59	Epidermal growth factor receptor status and Notch inhibition in non-small cell lung cancer cells. <i>Journal of Biomedical Science</i> , 2015, 22, 98.	2.6	15
60	Updates on Oxaliplatin-Induced Peripheral Neurotoxicity (OXAI PN). <i>Toxics</i> , 2015, 3, 187-197.	1.6	27
61	Chemotherapy-induced peripheral neuropathy in adults: a comprehensive update of the literature. <i>Cancer Management and Research</i> , 2014, 6, 135.	0.9	222
62	Cobalamin deficiency triggering de novo status epilepticus. <i>Epileptic Disorders</i> , 2014, 16, 138-139.	0.7	3
63	Long-term course of oxaliplatin-induced polyneuropathy: a prospective 2-year follow-up study. <i>Journal of the Peripheral Nervous System</i> , 2014, 19, 299-306.	1.4	67
64	Bortezomib-induced peripheral neurotoxicity: an update. <i>Archives of Toxicology</i> , 2014, 88, 1669-1679.	1.9	73
65	Correspondence between neurophysiological and clinical measurements of chemotherapy-induced peripheral neuropathy: secondary analysis of data from the PeriNomS study. <i>Journal of the Peripheral Nervous System</i> , 2014, 19, 127-135.	1.4	36
66	The combination of antitumor drugs, exemestane and erlotinib, induced resistance mechanism in H358 and A549 non-small cell lung cancer (NSCLC) cell lines. <i>Pharmaceutical Biology</i> , 2014, 52, 444-452.	1.3	10
67	Clinical pattern and associations of oxaliplatin acute neurotoxicity. <i>Cancer</i> , 2013, 119, 438-444.	2.0	179
68	Destructive Cervical Spine Osteoblastoma at C5 in a Young Patient Initially Presenting with Quadriplegia: Case Report and Review of the Literature. <i>Journal of Emergency Medicine</i> , 2013, 44, e1-e4.	0.3	6
69	Voltage-gated sodium channel polymorphisms play a pivotal role in the development of oxaliplatin-induced peripheral neurotoxicity: Results from a prospective multicenter study. <i>Cancer</i> , 2013, 119, 3570-3577.	2.0	86
70	Incidence of atypical acute nerve hyperexcitability symptoms in oxaliplatin-treated patients with colorectal cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2012, 70, 899-902.	1.1	37
71	NSCLC and the alternative pathway of NF- $\kappa$ B: uncovering an unknown relation. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2012, 460, 515-523.	1.4	19
72	Altered expression of NFY-C and RORA in colorectal adenocarcinomas. <i>Acta Histochemica</i> , 2012, 114, 553-561.	0.9	20

#	ARTICLE	IF	CITATIONS
73	Chemotherapy-induced peripheral neurotoxicity (CIPN): An update. <i>Critical Reviews in Oncology/Hematology</i> , 2012, 82, 51-77.	2.0	441
74	Incidence, characteristics, and associations of oxaliplatin-induced peripheral neuropathy in colorectal cancer patients: Results of a prospective, multicenter, international study.. <i>Journal of Clinical Oncology</i> , 2012, 30, 9090-9090.	0.8	0
75	Hemifacial spasm secondary to hyperhomocysteinaemia-associated cerebral small vessel disease. <i>Acta Neuropsychiatrica</i> , 2011, 23, 89-91.	1.0	0
76	Foreign accent syndrome caused by a left temporalâ€“parietal ischaemic stroke. <i>Acta Neuropsychiatrica</i> , 2011, 23, 249-251.	1.0	5
77	Assessing the Quality of Sleep in Greek Primary Caregivers of Patients With Secondary Progressive Multiple Sclerosis: A Cross-Sectional Study. <i>Journal of Pain and Symptom Management</i> , 2011, 42, 541-547.	0.6	17
78	Quality of life and emotional burden of primary caregivers: a caseâ€“control study of multiple sclerosis patients in Greece. <i>Quality of Life Research</i> , 2011, 20, 1663-1668.	1.5	28
79	Vitamin E for preventing chemotherapy-induced peripheral neuropathy. <i>Supportive Care in Cancer</i> , 2011, 19, 725-726.	1.0	11
80	Religiosity and its relation to quality of life in primary caregivers of patients with multiple sclerosis: a case study in Greece. <i>Journal of Neurology</i> , 2011, 258, 1114-1119.	1.8	13
81	The survivin -31 snp in human colorectal cancer correlates with survivin splice variant expression and improved overall survival. <i>Cellular Oncology (Dordrecht)</i> , 2011, 34, 381-391.	2.1	31
82	Cocaine Use and Abuse Triggering Sporadic Young-Onset Amyotrophic Lateral Sclerosis. <i>Neurodegenerative Diseases</i> , 2011, 8, 146-148.	0.8	1
83	F-Wave Characteristics as Surrogate Markers of Spasticity in Patients With Secondary Progressive Multiple Sclerosis. <i>Journal of Clinical Neurophysiology</i> , 2010, 27, 120-125.	0.9	14
84	Botulinum toxin type a for painful limbs moving extremities. <i>Movement Disorders</i> , 2010, 25, 125-125.	2.2	3
85	Molecularly Targeted Therapies for Dysimmune Neuropathies. <i>Molecular Medicine</i> , 2009, 15, 283-287.	1.9	4
86	Liability of the Voltage-Gated Sodium Channel Gene <i>SCN2A</i> R19K Polymorphism to Oxaliplatin-Induced Peripheral Neuropathy. <i>Oncology</i> , 2009, 77, 254-256.	0.9	17
87	Myasthenia gravis initially presenting with pseudo-internuclear ophthalmoplegia. <i>Neurological Sciences</i> , 2009, 30, 387-388.	0.9	6
88	Bilateral drop foot secondary to a primary tumor in the conus medullaris. <i>Muscle and Nerve</i> , 2008, 37, 778-780.	1.0	6
89	Peripheral nerve damage associated with administration of taxanes in patients with cancer. <i>Critical Reviews in Oncology/Hematology</i> , 2008, 66, 218-228.	2.0	211
90	Multiple Sclerosis and Reproductive Risks in Women. <i>Reproductive Sciences</i> , 2008, 15, 755-764.	1.1	20

#	ARTICLE	IF	CITATIONS
91	A review on oxaliplatin-induced peripheral nerve damage. <i>Cancer Treatment Reviews</i> , 2008, 34, 368-377.	3.4	275
92	Incidence and characteristics of peripheral neuropathy during oxaliplatin-based chemotherapy for metastatic colon cancer. <i>Acta Oncologica</i> , 2007, 46, 1131-1137.	0.8	80
93	The Usefulness of Nerve Conduction Studies in Objectively Assessing Oxaliplatin-Induced Peripheral Neuropathy. <i>Oncologist</i> , 2007, 12, 1371-1372.	1.9	10
94	Intracerebral haemorrhage as a rare complication of HSV-1 meningoencephalitis: Case report and review of the literature. <i>Scandinavian Journal of Infectious Diseases</i> , 2006, 38, 63-66.	1.5	17
95	Is advanced age associated with increased incidence and severity of chemotherapy-induced peripheral neuropathy?. <i>Supportive Care in Cancer</i> , 2006, 14, 223-229.	1.0	71
96	Preventing Paclitaxel-Induced Peripheral Neuropathy: A Phase II Trial of Vitamin E Supplementation. <i>Journal of Pain and Symptom Management</i> , 2006, 32, 237-244.	0.6	113
97	Paclitaxel plus carboplatin-induced peripheral neuropathy. <i>Journal of Neurology</i> , 2005, 252, 1459-1464.	1.8	28
98	Peripheral neuropathy induced by administration of cisplatin- and paclitaxel-based chemotherapy. Could it be predicted?. <i>Supportive Care in Cancer</i> , 2005, 13, 647-651.	1.0	54
99	Psychosocial effects and evaluation of the health-related quality of life in patients suffering from well-controlled epilepsy. <i>Journal of Neurology</i> , 2004, 251, 310-313.	1.8	18